[1]Patent:CN106187857,2016,A.Locationinpatent:Paragraph0014;0026;0027;0028;0029;0030-0033
[2]Patent:CN107188842,2017,A.Locationinpatent:Paragraph0037-0044
[3]Patent:CN105348172,2016,A.Locationinpatent:Paragraph0070;0071;0072
[4]Patent:CN106146384,2016,A.Locationinpatent:Paragraph0039;0040;0041
[5]Patent:US2007/155791,2007,A1.Locationinpatent:Page/Pagecolumn14
[6]Patent:WO2014/74846,2014,A1.Locationinpatent:Page/Pagecolumn21
[7]Patent:WO2014/151180,2014,A1.Locationinpatent:Paragraph0075
[8]Patent:US9272035,2016,B2.Locationinpatent:Page/Pagecolumn23-24
[9]Patent:WO2015/175956,2015,A1.Locationinpatent:Paragraph0189
[10]Patent:US2016/128981,2016,A1.Locationinpatent:Paragraph0217
[11]Patent:US9387195,2016,B2.Locationinpatent:Paragraph27;28
[12]Patent:WO2018/61034,2018,A1.Locationinpatent:Page/Pagecolumn12
[13]Patent:EP3096749,2019,B1.Locationinpatent:Paragraph0082
[14]Patent:EP3157520,2019,B1.Locationinpatent:Paragraph0101
[15]Patent:WO2016/169533,2016,A1.Locationinpatent:Page/Pagecolumn11;12
[16]Patent:WO2016/189486,2016,A1.Locationinpatent:Page/Pagecolumn14;15;16
[17]Patent:WO2019/73431,2019,A1.Locationinpatent:Page/Pagecolumn14;20
[18]Patent:CN105622380,2016,A.Locationinpatent:Paragraph0076;0077;0078;0079;0080
[19]Patent:CN105218428,2016,A.Locationinpatent:Paragraph0012;0021;0222
[20]Patent:WO2017/33116,2017,A1.Locationinpatent:Paragraph00116;00118-00127
[21]Patent:WO2017/85568,2017,A1.Locationinpatent:Page/Pagecolumn21-22
[22]Patent:WO2017/196192,2017,A1.Locationinpatent:Page/Pagecolumn31-32
[23]Patent:WO2017/94031,2017,A2.Locationinpatent:Page/Pagecolumn15
[24]Patent:WO2019/21303,2019,A1.Locationinpatent:Page/Pagecolumn26;28-34
[25]Patent:CN110467557,2019,A.Locationinpatent:Paragraph0031-0039;0044
[1]Patent:CN105294534,2016,A.Locationinpatent:Paragraph0030;0031
[2]Patent:WO2017/59040,2017,A1.Locationinpatent:Paragraph00120
[3]Patent:WO2016/192694,2016,A1.Locationinpatent:Page/Pagecolumn22
[4]Patent:CN106995401,2017,A.Locationinpatent:Paragraph0016;0063;0064;0066-89
[5]Patent:CN105348172,2016,A.Locationinpatent:Paragraph0068;0069
[6]Patent:WO2016/161996,2016,A1.Locationinpatent:Page/Pagecolumn24
[7]Patent:CN105085373,2018,B.Locationinpatent:Paragraph0030;0033;0034
[8]Patent:CN106866493,2017,A.Locationinpatent:Paragraph0047-0048
[9]ChemCatChem,2019,vol.11,p.5808-5813
[10]JournalofMedicinalChemistry,2009,vol.52,p.1522-1524
[11]Patent:WO2018/203192,2018,A1.Locationinpatent:Page/Pagecolumn12;13
[12]Patent:WO2016/202806,2016,A1.Locationinpatent:Page/Pagecolumn20
[13]Patent:WO2017/46319,2017,A1.Locationinpatent:Page/Pagecolumn21
[14]Patent:EP3157520,2019,B1.Locationinpatent:Paragraph0097
[15]Patent:US2014/81032,2014,A1.Locationinpatent:Paragraph0320;0321
[16]Patent:WO2016/199031,2016,A1.Locationinpatent:Paragraph33;34;35
[17]Patent:WO2017/85568,2017,A1.Locationinpatent:Page/Pagecolumn20
[18]Patent:CN107698485,2018,A.Locationinpatent:Paragraph0027;0028;0029;0030;0031
[1]CurrentPatentAssignee:AMGENINC-US2012/178708,2012,A1Locationinpatent:Page/Pagecolumn18
[1]CurrentPatentAssignee:AMGENINC-US2012/178708,2012,A1Locationinpatent:Page/Pagecolumn18
[1]Patent:US2014/81032,2014,A1
[2]Patent:CN105330586,2016,A
[3]Patent:WO2016/174685,2016,A1
[4]Patent:WO2016/199031,2016,A1
[5]Patent:WO2016/199031,2016,A1
[6]Patent:WO2016/199031,2016,A1
[7]Patent:WO2016/199031,2016,A1
[8]Patent:WO2016/189486,2016,A1
[9]Patent:CN106866493,2017,A
Title: Apremilast: a PDE4 inhibitor for the treatment of psoriatic arthritis.
Journal: Expert opinion on pharmacotherapy 20150501
Title: Apremilast is a selective PDE4 inhibitor with regulatory effects on innate immunity.
Journal: Cellular signalling 20140901
Title: A review of phosphodiesterase-inhibition and the potential role for phosphodiesterase 4-inhibitors in clinical dermatology.
Journal: Dermatology online journal 20140516
Title: Novel systemic drugs for psoriasis: mechanism of action for apremilast, a specific inhibitor of PDE4.
Journal: Journal of the American Academy of Dermatology 20130601
Title: Phosphodiesterase 4-targeted treatments for autoimmune diseases.
Journal: BMC medicine 20130101
Title: Efficacy of apremilast in the treatment of moderate to severe psoriasis: a randomised controlled trial.
Journal: Lancet (London, England) 20120825
Title: Apremilast: a step forward in the treatment of psoriasis?
Journal: Lancet (London, England) 20120825
Title: Novel systemic drugs under investigation for the treatment of psoriasis.
Journal: Journal of the American Academy of Dermatology 20120701
Title: Apremilast mechanism of action and application to psoriasis and psoriatic arthritis.
Journal: Biochemical pharmacology 20120615
Title: A phase 2, open-label, investigator-initiated study to evaluate the safety and efficacy of apremilast in subjects with recalcitrant allergic contact or atopic dermatitis.
Journal: Journal of drugs in dermatology : JDD 20120301
Title: [New therapeutic targets in psoriatic arthritis].
Journal: Reumatologia clinica 20120301
Title: Efficacy and safety of apremilast in chronic cutaneous sarcoidosis.
Journal: Archives of dermatology 20120201
Title: Disposition, metabolism and mass balance of [(14)C]apremilast following oral administration.
Journal: Xenobiotica; the fate of foreign compounds in biological systems 20111201
Title: Apremilast, a cAMP phosphodiesterase-4 inhibitor, demonstrates anti-inflammatory activity in vitro and in a model of psoriasis.
Journal: British journal of pharmacology 20100201
Title: Apremilast, a novel PDE4 inhibitor, inhibits spontaneous production of tumour necrosis factor-alpha from human rheumatoid synovial cells and ameliorates experimental arthritis.
Journal: Arthritis research & therapy 20100101
Title: Discovery of (S)-N-[2-[1-(3-ethoxy-4-methoxyphenyl)-2-methanesulfonylethyl]-1,3-dioxo-2,3-dihydro-1H-isoindol-4-yl] acetamide (apremilast), a potent and orally active phosphodiesterase 4 and tumor necrosis factor-alpha inhibitor.
Journal: Journal of medicinal chemistry 20090326
Title: An open-label, single-arm pilot study in patients with severe plaque-type psoriasis treated with an oral anti-inflammatory agent, apremilast.
Journal: Current medical research and opinion 20080501
Title: 10th anniversary Inflammation and Immune Diseases Drug Discovery and Development Summit. 20-21 March 2006, New Brunswick, USA.
Journal: Expert opinion on investigational drugs 20060601
Title: CC-1088 Celgene.
Journal: Current opinion in investigational drugs (London, England : 2000) 20050501
Title: CC-10004 .
Journal: Current opinion in investigational drugs (London, England : 2000) 20050501
Title: The effects of selective cytokine inhibitory drugs (CC-10004 and CC-1088) on VEGF and IL-6 expression and apoptosis in myeloma and endothelial cell co-cultures.
Journal: British journal of haematology 20040201
Title: Perez-Aso M, et al. Apremilast, a novel phosphodiesterase 4 (PDE4) inhibitor, regulates inflammation through multiple cAMP downstream effectors. Arthritis Res Ther. 2015 Sep 15;17:249.
Title: Chen LG, et al. Determination of Apremilast in Rat Plasma by UPLC-MS-MS and Its Application to a Pharmacokinetic Study. J Chromatogr Sci. 2016 Sep;54(8):1336-40.
